Peter Finan
Partner @ Epidarex Capital
Edinburgh, United Kingdom
Peter Finan is a Series A investor at Epidarex Capital in Edinburgh focused on Biotechnology and Health Care. Pete Finan is the former head of the Novartis Institute of BioMedical Research (NIBR) site in the UK where he oversaw the activities of 350 scientists and clinicians working in the respiratory disease area. Prior to this he was an Executive Director in the Developmental and Molecular Pathways department at NIBR in Cambridge, Massachusetts leadingprograms in oncology, inflammation and regenerative medicine and Head of Biology at Karus Therapeutics. Pete is also a Partner at Epidarex Capital and has led / co-led the financing of six new companies in the Epidarex portfolio. He has a BSc and PhD from the University of Leeds.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 71%
Last updated:
For AI agents: llms.txt
Industries Peter Finan invests in
Stages Peter Finan invests in
Countries Peter Finan invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (43%)
- Health Care 2 (29%)
- Therapeutics 2 (29%)
- Genetics 1 (14%)
- Biopharma 1 (14%)
Stage
- Series A 3 (43%)
- Seed 1 (14%)
- Series B 1 (14%)
Country
- United Kingdom 3 (43%)
- Canada 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor. | $16.3M / Series B / Sep 09, 2024 | ||
| IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor. | $41.2M / Series B / Mar 02, 2022 | ||
| Leucid Bio is a pioneering biotech company developing cell therapies for refractory cancers, especially solid tumors. Leucid was founded to translate 20 years of King's College London (King's) research in the CAR-T field and is led by a highly experienced management team with both scientific and commercial expertise. As part ofLeucid's ongoing relationship with King's, it benefits from exclusive access to and resources from the deep scientific, clinical, and manufacturing expertise of Dr. Maher and his academic team of immuno-oncology experts. | $15.9M / Series A / Oct 21, 2021 | ||
| IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor. | $6.4M / Series A / Nov 30, 2018 | ||
| AdoRx Therapeutics is pursuing the discovery of new therapeutics for cancer based on modulation of the adenosine pathway. High levels of adenosine in the tumour microenvironment enable cancer to evade the immune system. AdoRx’s lead programs are focused on the design of “fit for purpose” adenosine receptor antagonists that will overcome the effectsof high adenosine levels. AdoRx Therapeutics is a UK-based drug discovery company and backed by investment from Epidarex Capital and Sixth Element Capital. The AdoRx leadership team have discovered in excess of 25 clinical candidates and have greater than 60 years combined experience of drug discovery in biotech and pharma. | $10M / Series A / Jun 21, 2018 | ||
| IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor. | $2.6M / Series A | ||
| Clean Metals Recycling is a metal recycling company that uses cutting-edge environmental services to turn industrial waste into valuable metal byproducts. | $4.2M / Seed |
Co-Investors
About Epidarex Capital
Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, international corporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.
Epidarex Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Elizabeth Roper
Partner
|
|||
|
Peter Finan
Partner
|
|||
Terri Burke
Venture Partner
|
|||
|
Kyparissia Sirinakis
Founder & Managing Partner
|
|||
|
Sinclair Dunlop
Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Peter Finan invest in?
Peter Finan invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Seed stage. Most of the 7 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Peter Finan?
Public channels for Peter Finan include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Peter Finan last invest?
The most recent investment recorded for Peter Finan closed in Sep 2024. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
